J
Julio Rosenstock
Researcher at University of Texas Southwestern Medical Center
Publications - 423
Citations - 39792
Julio Rosenstock is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 94, co-authored 364 publications receiving 32784 citations. Previous affiliations of Julio Rosenstock include Medical City Dallas Hospital & Pfizer.
Papers
More filters
Journal ArticleDOI
845-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline HbA1c, Insulin Dose, and BMI
Philip Holmes,Rory J. McCrimmon,Julio Rosenstock,Matthias Blüher,K-O Pegelow,Lydie Melas-Melt,Khier Djaballah,Francesco Giorgino +7 more
TL;DR: Primary SoliMix findings for iGlarLixi vs. BIAsp 30 were consistent across baseline HbA1c and BMI subgroups but inconsistent for baseline insulin dose, and both primary objectives were met.
Journal ArticleDOI
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Melanie J. Davies,Melanie J. Davies,Julio Rosenstock,Amar Ali,David Russell-Jones,Elisabeth Souhami,Karen Palmer,Chen Ji,Elisabeth Niemoeller,Neil Skolnik +9 more
TL;DR: The LixiLan-O study (NCT02058147) as mentioned in this paper evaluated the efficacy and safety of iGlarLixi (the titratable fixed-ratio combination of insulin glargine 100 u/mL plus lixisenatide [lixi]), in adults with type 2 diabetes (T2D) with glycated haemoglobin (HbA1c) levels ≥8% (≥64 mmol/mol).
Journal ArticleDOI
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
Hertzel C. Gerstein,Zhuoru Li,Chinthanie Ramasundarahettige,Seungjae Baek,Kelley R. Branch,Stefano Del Prato,Carolyn S.P. Lam,Renato D. Lopes,Richard E. Pratley,Julio Rosenstock,Naveed Sattar +10 more
TL;DR: The AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial as discussed by the authors showed that adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpe glenatides to usual care reduced major adverse cardiovascular events (MACE) and on all the secondary composite cardiovascular and kidney outcomes.
Journal ArticleDOI
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Julio Rosenstock,Juan P. Frias,Ania M. Jastreboff,Yu Du,Jitong Lou,Sirel Gurbuz,Melissa K. Thomas,Mark L. Hartman,Axel Haupt,Zvonko Milicevic,Tamer Coskun +10 more